236 related articles for article (PubMed ID: 30954635)
1. Repurposing disulfiram for treatment of Staphylococcus aureus infections.
Thakare R; Shukla M; Kaul G; Dasgupta A; Chopra S
Int J Antimicrob Agents; 2019 Jun; 53(6):709-715. PubMed ID: 30954635
[TBL] [Abstract][Full Text] [Related]
2. Repurposing disulfiram to target infections caused by non-tuberculous mycobacteria.
Das S; Garg T; Chopra S; Dasgupta A
J Antimicrob Chemother; 2019 May; 74(5):1317-1322. PubMed ID: 30753528
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of new quinazolin-4(3H)-one derivatives as potent antibacterial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis.
Gatadi S; Gour J; Shukla M; Kaul G; Dasgupta A; Madhavi YV; Chopra S; Nanduri S
Eur J Med Chem; 2019 Aug; 175():287-308. PubMed ID: 31096152
[TBL] [Abstract][Full Text] [Related]
4. Repurposing Thiram and Disulfiram as Antibacterial Agents for Multidrug-Resistant Staphylococcus aureus Infections.
Long TE
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674046
[TBL] [Abstract][Full Text] [Related]
5. Repurposing ethyl bromopyruvate as a broad-spectrum antibacterial.
Kumar A; Boradia VM; Thakare R; Singh AK; Gani Z; Das S; Patidar A; Dasgupta A; Chopra S; Raje M; Raje CI
J Antimicrob Chemother; 2019 Apr; 74(4):912-920. PubMed ID: 30689890
[TBL] [Abstract][Full Text] [Related]
6. Oxiconazole Potentiates Gentamicin against Gentamicin-Resistant Staphylococcus aureus
Kaul G; Akhir A; Shukla M; Shafi H; Akunuri R; Pawar G; Ghouse M; Srinivas N; Chopra S
Microbiol Spectr; 2023 Aug; 11(4):e0503122. PubMed ID: 37428033
[TBL] [Abstract][Full Text] [Related]
7. A High-Throughput Screening Approach To Repurpose FDA-Approved Drugs for Bactericidal Applications against Staphylococcus aureus Small-Colony Variants.
Trombetta RP; Dunman PM; Schwarz EM; Kates SL; Awad HA
mSphere; 2018 Oct; 3(5):. PubMed ID: 30381352
[TBL] [Abstract][Full Text] [Related]
8. Nitazoxanide potentiates linezolid against linezolid-resistant Staphylococcus aureus in vitro and in vivo.
Kaul G; Akhir A; Shukla M; Rawat KS; Sharma CP; Sangu KG; Rode HB; Goel A; Chopra S
J Antimicrob Chemother; 2022 Aug; 77(9):2456-2460. PubMed ID: 35748613
[TBL] [Abstract][Full Text] [Related]
9. Pyrvinium pamoate potentiates levofloxacin against levofloxacin-resistant
Kaul G; Karale UB; Akhir A; Shukla M; Saxena D; Rode HB; Chopra S
Future Microbiol; 2022 Dec; 17():1475-1486. PubMed ID: 36314364
[TBL] [Abstract][Full Text] [Related]
10. Repurposing Ivacaftor for treatment of Staphylococcus aureus infections.
Thakare R; Singh AK; Das S; Vasudevan N; Jachak GR; Reddy DS; Dasgupta A; Chopra S
Int J Antimicrob Agents; 2017 Sep; 50(3):389-392. PubMed ID: 28694231
[TBL] [Abstract][Full Text] [Related]
11. Repurposing auranofin for the treatment of cutaneous staphylococcal infections.
Thangamani S; Mohammad H; Abushahba MF; Sobreira TJ; Seleem MN
Int J Antimicrob Agents; 2016 Mar; 47(3):195-201. PubMed ID: 26895605
[TBL] [Abstract][Full Text] [Related]
12. Identification and bioevaluation of SRI-12742 as an antimicrobial agent against multidrug-resistant Acinetobacter baumannii.
Shukla M; Soni I; Matsuyama K; Tran T; Tanga M; Gong L; Chopra S
Int J Antimicrob Agents; 2018 Jul; 52(1):22-27. PubMed ID: 29501820
[TBL] [Abstract][Full Text] [Related]
13. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
14. Biocatalytic synthesis of diaryl disulphides and their bio-evaluation as potent inhibitors of drug-resistant Staphylococcus aureus.
Saima ; Soni I; Lavekar AG; Shukla M; Equbal D; Sinha AK; Chopra S
Drug Dev Res; 2019 Feb; 80(1):171-178. PubMed ID: 30565263
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of new 4-oxoquinazolin-3(4H)-yl)benzoic acid and benzamide derivatives as potent antibacterial agents effective against multidrug resistant Staphylococcus aureus.
Gatadi S; Gour J; Shukla M; Kaul G; das S; Dasgupta A; Madhavi YV; Chopra S; Nanduri S
Bioorg Chem; 2019 Mar; 83():569-579. PubMed ID: 30471579
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo activities of echinomycin against clinical isolates of Staphylococcus aureus.
Park YS; Shin WS; Kim SK
J Antimicrob Chemother; 2008 Jan; 61(1):163-8. PubMed ID: 17967852
[TBL] [Abstract][Full Text] [Related]
17. Biological evaluation of diphenyleneiodonium chloride (DPIC) as a potential drug candidate for treatment of non-tuberculous mycobacterial infections.
Singh AK; Thakare R; Karaulia P; Das S; Soni I; Pandey M; Pandey AK; Chopra S; Dasgupta A
J Antimicrob Chemother; 2017 Nov; 72(11):3117-3121. PubMed ID: 28961864
[TBL] [Abstract][Full Text] [Related]
18. Novel Inhibitors of Staphyloxanthin Virulence Factor in Comparison with Linezolid and Vancomycin versus Methicillin-Resistant, Linezolid-Resistant, and Vancomycin-Intermediate Staphylococcus aureus Infections in Vivo.
Ni S; Wei H; Li B; Chen F; Liu Y; Chen W; Xu Y; Qiu X; Li X; Lu Y; Liu W; Hu L; Lin D; Wang M; Zheng X; Mao F; Zhu J; Lan L; Li J
J Med Chem; 2017 Oct; 60(19):8145-8159. PubMed ID: 28880552
[TBL] [Abstract][Full Text] [Related]
19. Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1997 Aug; 46(33):765-6. PubMed ID: 9272582
[TBL] [Abstract][Full Text] [Related]
20. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
Hegde SS; Skinner R; Lewis SR; Krause KM; Blais J; Benton BM
J Antimicrob Chemother; 2010 Apr; 65(4):725-8. PubMed ID: 20139142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
